Concepts for discussion 1.synopses – don’t overdo it 2.how comfortable were you with Wagner paper, Mintun, Farde? 3.non-specific vs specific binding 4.how.

Slides:



Advertisements
Similar presentations
PHARMACOKINETIC MODELS
Advertisements

Brookhaven Science Associates U.S. Department of Energy Gene-Jack Wang, M.D. The Addiction-Obesity Connection Brookhaven Science Associates U.S. Department.
Positron Emission Tomography for Antidepressant Binding Sites Paul Cumming, Dirk Bender, Albert Gjedde, Kathi Marthi, Svend Borup Jensen, and Donald Smith.
Lecture #4 Chemical Reactions. Basic Properties of Chemical Reactions Stoichiometry -- chemistry Relative rates – thermodynamics; K eq = f(P,T) Absolute.
AOSC 634 Air Sampling and Analysis Lecture 1 Measurement Theory Performance Characteristics of instruments Nomenclature and static response Copyright Brock.
ANALYSIS OF PET STUDIES PET Basics Course 2006 Turku PET Centre Vesa Oikonen
T (B+F)/F B/F ‘late’ or ‘early’ image? whose brain is this? why a CT scan first? why increasing contrast w/ time? why increasing noise w/time?
MODELLING AND PARAMETER ESTIMATION IN PET Vesa Oikonen Turku PET Centre
Q: What is this dog thinking about?. He’s thinking about two things: 1. Saturable processes. 2. Solving the FDG model.
Brain… The Final Frontier…. Lets go on a “Fantastic Voyage” Blood Flow Metabolism Permeability Receptor Binding Gene Expression Neurotransmission Transmitter.
ANALYSIS OF PET STUDIES Turku PET Centre V Oikonen PET Raw Data (sinogram) Results Parametric Sinogram PET Image Parametric Image Regional TACs.
Imaging Drugs in the Brain ENAS 880 / NSCI 523 Fall 2010 Morris/Cosgrove kelly
Radiation Therapy (RT). What is cancer? Failure of the mechanisms that control growth and proliferation of the cells Uncontrolled (often rapid) growth.
What are some of the issues in choosing bolus vs bolus+infusion? Which one predicts equilibrium coefficients? Which one achieves equilibrium? Which one.
VISUALIZING ALL THE FITS: Evaluating The Quality And Precision Of Parametric Images Created From Direct Reconstruction Of PET Sinogram Data Evan D. Morris.
Imaging Drugs in the Brain ENAS 880 / NSCI 523 Fall 2010 Morris/Cosgrove kelly
Goal:. design 11C-FLB457 perospirone Why? In the Arakawa paper, where does the baseline (aka ‘control’) data come from? From Vernaleken et al…
PHYSICS IN NUCLEAR MEDICINE: QUANTITAITVE SPECT AND CLINICAL APPLICATIONS Kathy Willowson Department of Nuclear Medicine, Royal North Shore Hospital University.
Numerical Enzymology Generalized Treatment of Kinetics & Equilibria Petr Kuzmič, Ph.D. BioKin, Ltd. DYNAFIT SOFTWARE PACKAGE.
Week 4 - Biopharmaceutics and Pharmacokinetics
Positron Emission Tomography: Tool to Facilitate Drug Development and to Study Pharmacokinetics Robert B. Innis, MD, PhD Molecular Imaging Branch National.
H. Koivunoro1, E. Hippelänen1, I. Auterinen2, L. Kankaanranta3, M
The color was brownish The volume was 6 mL The weight was 11.5 g What’s the difference between these three pieces of data?
Presentation Schedule. Homework 8 Compare the tumor-immune model using Von Bertalanffy growth to the one presented in class using a qualitative analysis…
Class 4 Mass transport in sensors: interplay among diffusion, convection and binding kinetics Plan: review of last week new material go over homework Restatement.
Receptor Occupancy estimation by using Bayesian varying coefficient model Young researcher day 21 September 2007 Astrid Jullion Philippe Lambert François.
PET Module Ana Beatriz Solana, MS Qu Tian (Teresa), MS Instructor: Dr. Charles Laymon.
PHARMACOKINETIC MODELS
1-Compartment Oral Dosing 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following.
Cognitive Psychology PSYC231 Cognition and the Brain: Basic Principles 2 Dr. Jan Lauwereyns, EA619, ext
PET Yale Human Imaging Tracer Kinetic Modeling Novel Radiochemistry.
HuBio 543 September 6, 2007 Frank F. Vincenzi
Biological Explanations for Schizophrenia
Linearized models in PET Vesa Oikonen Turku PET Centre – Modelling workshop Modelling workshop
Comparison of methodologies for the assessment of dopamine receptor binding in subregions of the striatum Functional Neuroimaging Lab School of Psychology.
GENERATION OF PARAMETRIC IMAGES PROSPECTS PROBLEMS Vesa Oikonen Turku PET Centre
11 Motivation  Nicotine causes DA release in the striatum, part of the mesolimbic DA pathway which mediates reinforcing behaviors (Martin-Soelch et al,
Time Plasma Conc (hr) (mg/L) Below limit of detection 1 Compartment IV Analysis & Renal Elimination 500 mg of tobramycin.
Other uses of DNA microarrays
Electrostatic field in dielectric media When a material has no free charge carriers or very few charge carriers, it is known as dielectric. For example.
Describe and Evaluate Biological Explanations for Schizophrenia.
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Modafinil on Dopamine and Dopamine Transporters.
Designing a Computer Simulation Tool for PET Neuroimaging
Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18F]AMG 580 in non-human primates  Dah-Ren Hwang, Essa Hu, Jennifer R. Allen,
Volume 139, Issue 3, Pages e6 (September 2010)
Assessment of [3H]Diprenorphine (DPN) and [11C]Carfentanil (CFN) to Endogenous Opioid Peptide (EOP) Release Darren R. Quelch1, Christine A. Parker1,2,
Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin  Adam J. Hall, Michael J. Chappell, John A.D.
OK. What if we don’t care about the kinetics of a particular tracee molecule (e.g., glucose). Rather, we care about counting up the number of one type.
Driven SHM k m Last time added damping. Got this kind of solution that oscillates due to initial conditions, but then decays. This is an important concept.
International Neurourology Journal 2012;16:
Species Comparison of the Binding Properties for Three D2/3-DAR
Tissue response compared to receptor occupation
Masahiro Ueda, Tatsuo Shibata  Biophysical Journal 
Model Part – Yiming Weng
Signal and Noise in fMRI
Quantitative PET Imaging; from Research to Clinical Use
Selected Bioavailability and Pharmacokinetic Calculations
Receptive substances proposed 1909 by Langley (nicotine)
Large Currents Generate Cardiac Ca2+ Sparks
Franco Pestilli, Marisa Carrasco, David J. Heeger, Justin L. Gardner 
Project #1: Drug Kinetics in Genetically Modified Mice
Driven SHM k m Last time added damping. Got this kind of solution that oscillates due to initial conditions, but then decays. This is an important concept.
Franco Pestilli, Marisa Carrasco, David J. Heeger, Justin L. Gardner 
Blood/Subcutaneous Glucose Dynamics Estimation Techniques
A Dynamic Corral Model of Receptor Trafficking at a Synapse
Plot of BOUND against FREE ligand
Fig. 1. In vivo–in vitro validation of [11C]UCB-J as a synaptic density biomarker in the baboon brain. In vivo–in vitro validation of [11C]UCB-J as a synaptic.
M. Maravall, Z.F. Mainen, B.L. Sabatini, K. Svoboda 
R.P. Schuhmeier, B. Dietze, D. Ursu, F. Lehmann-Horn, W. Melzer 
Presentation transcript:

concepts for discussion 1.synopses – don’t overdo it 2.how comfortable were you with Wagner paper, Mintun, Farde? 3.non-specific vs specific binding 4.how to measure non-specific binding (displacement) 5.can we do displacement in humans? maybe… 6.qualitative imaging vs quantitative imaging 7.“tracer” vs “drug” … vs “transmitter” 8.how to create a kinetic (compartmental) model for a PET tracer 9.what is a compartment? 10.what is a mass-balance? Conservation of mass (not conservation of radioactivity; not conservation of concentration…) 11.what do we measure with PET? But what quantity do we need to model? 12.why arterial sampling (need input function) 13.are all parameters estimatable? consider y = m*n*x + b 14.what are simulations good for? 15.binding potential – what does it represent? 16.Binding potential may be an equilibrium measure, but do we need to reach equilibrium to measure it? (how ‘bout your adult height?) 17.drug occupancy – how do we measure it with PET? 18.how did Farde do it? What assumptions did he make? Do you accept them?

ENAS 880 – Sept 13, 2011

Recall from last time… Tracer in each state has a unique temporal trajectory Time (minutes) tracer concentration Plasma Free Bound What the PET scanner sees which is which ? earlylate striatum cerebellum

why is most of the brain blue? are these “early” or “late” images? is this structural or functional? is this a ‘detection’ or a ‘characterization’ experiment? Fowler et al., Science & Practice Perspectives, April 2007, 4-16

t (B+F)/F B/F ‘late’ or ‘early’ image? whose brain is this? why a CT scan first? why increasing contrast w/ time? why increasing noise w/time? what is the point of excess cold spiperone? what do we learn from it re the caudate? can we compare these numbers across scans? why divide by cerebellum value? could we do this exp’t in a human?

Main points/questions/criticisms – Wagner et al. 1.so who really did the “first in vivo scan” of DA receptors in a primate? 2.how did this get into Science (and not Mintun)? 3.can we assume that cerebellum is exactly the same as the ‘free’ in the striatum? 4.whose brain was it?

First PET Image Of D2 Receptors in Brain

where do error bars come from? (if so) is the Y axis correct? where does “specific putamen” come from – special brain area known only in Sweden? what is plotted? (B vs F) – how did they get these values? how did they get 5 data points what is the slope near origin? what is the assymptotic value for Y axis? where does “expected spec binding” come from? Is this a safe comparison? what factors are ignored? understand this? got equilibrium?

raclo in cereb (assume = free) --> plug into Bmax*Free/[Kd + Free] using Bmax and Kd from Healthy controls --> predicts B at equilib for schizo patients. Compare to actual B measured for patients (via [striat-cereb] per injected dose – I hope) first ‘drug occupancy’ study with PET? receptor occup =  B/B (fractional change in binding due to presence of bound drug) = (B predicted – B actual )/B predicted claim: uniformity of occupancy of D2 by different drugs suggests that occupancy level is related to efficacy.

What’s all this about models in PET? Bound raclopride Free raclopride Plasma raclopride ‘stuck’ raclopride Dopaminergic synapse

The modeling process (b) PFB N (c) (d) (a) Imagine a living brain Consider the relevant neurochemistry Abstract the neurochemistry into a series of connected pools Describe exchange between pools by a series of differential equations Morris, E.D., C.J. Endres, K. Schmidt, B.T. Christian, R.F. Muzic, R.E. Fisher. Kinetic Modeling in PET. In Emission Tomography: The Fundamentals of PET and SPECT, ed. M. Wernick and N. Aarsvold. Academic Press. Amsterdam, Netherlands, 2004, pp

PFB typically written as… what’s all this about? what is  ? conservation of mass under what condition? what is the blue? what is the fraction of P that is blue – according to Mintun? according to us? Mintun: can’t estimate Bmax and rate constants from high spec act expm’t

parameter estimation – what is it? why is it iterative? simulations? what are they good for? what are they used for here? sensitivity analysis – huh? k on *B max = B max k off K D BP is an equilibrium ratio (has no units of time or rates) but we can get it from a TRANSIENT experiment.

anything tricky about using an in vitro sample for anatomy? what’s the difference between expt 1 and expt 2 in same baboon? why didn’t they estimate BP in 2 nd study?

Schematic Diagram of Ligand Binding “Rest” condition endogenous NTunlabeled tracerradiolabeled tracer BP = B/F at steady state

Schematic Diagram of Ligand Binding “Rest” condition endogenous NTunlabeled tracerradiolabeled tracer loss of receptors BP ↓

Schematic Diagram of Ligand Binding DA-release condition endogenous NTunlabeled tracerradiolabeled tracer DA ↑ BP ↓

 BP is the (fractional) difference in BP between conditions  BP= (BP 1 -BP 2 )/BP 1

terms for next week: Sept 20 displacement release endogenous simulation what is Logan proving by her simulations? where they get their parameter vals what things might be causing DA release in Koepp expt? what might have been a better control condition(s)? what do (+) changes in binding potential (Fig 2) mean? what is the ‘proof’ that DA release is being measured? what is being optimized in Morris paper? where do they get their parameter vals?